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Glial activation and increased inﬂammation characterize neuropathology in Alzheimer’s disease (AD). The aim was to
develop a model for studying phagocytosis of β-amyloid (Aβ) peptide by human microglia and to test eﬀects thereupon by
immunomodulatory substances. Human CHME3 microglia showed intracellular Aβ1–42 colocalized with lysosome-associated
membrane protein-2, indicating phagocytosis. This was increased by interferon-γ, and to a lesser degree with Protollin, a
proteosome-based adjuvant. Secretion of brain-derived neurotrophic factor (BDNF) was decreased by Aβ1–42 and by interferon-
γ and interleukin-1β. These cytokines, but not Aβ1–42, stimulated interleukin-6 release. Microglia which phagocytosed Aβ1–42
exhibited a higher degree of expression of interleukin-1 receptor type I and inducible nitric oxide synthase. In conclusion, we
show that human microglia are able to phagocytose Aβ1–42 and that this is associated with expression of inﬂammatory markers.
Aβ1–42 and interferon-γ decreased BDNF secretion suggesting a new neuropathological role for Aβ1–42 and the inﬂammation
accompanying AD.
1.Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia. The major pathological hallmarks of AD besides
neuronal loss are amyloid plaques and neuroﬁbrillary tan-
gles (NFTs). Both amyloid plaques and NFTs have been
implicated in neuronal impairment and death in a large
numberofstudies.Althoughagreatdealofcontroversyexists
about the relative importance of amyloid plaques contra
NFTs in AD [1], there is an overwhelming body of evidence
showing that amyloid plaques and the peptides they are
composed of are culprits in the neurodegenerative processes
in AD [2]. The main component of amyloid plaques is the
β-amyloid (Aβ)p e p t i d e ,t h a ti ss e c r e t e db yn e u r o n sa n d
other cells through cleavage of the larger, membrane-bound,
amyloid precursor protein (APP). APP can be processed by
two major pathways: the amyloidogenic pathway that yields
Aβ, and the nonamyloidogenic yielding fragments believed
to be nonpathogenic. The Aβ peptides are prone to self-
aggregation and deposition into insoluble plaques. This is
especially true for the 42 amino acid form (Aβ1–42), which
is the predominant form in the dense core plaques [3].
Aβ-species also exist in the forms of soluble monomers
and oligomers which similarly to the amyloid plaques are
more abundant in the AD brain than in the non-AD
brain [4]. Somehow, the balance between production and
clearance/degradation of Aβ is disturbed in AD.
Damage to brain tissue induces an inﬂammation, a
response which is present in many, if not all neurodegener-
ative conditions. In the central nervous system (CNS), glial
cells, that is, microglia and astrocytes, represent the main
source of inﬂammatory reactions. In normal conditions, glia
have supportive functions, including maintenance of ionic
homeostasis, clearance of neurotransmitters, and in the case
of astrocytes, providing nutrients to the energy-demanding
work of the neurons [5]. Glial, particularly microglial,
cell responses can also serve in the elimination of debris
from damaged cells and to remove pathogens. Removal of
pathogens is executed by the process of phagocytosis, a2 International Journal of Alzheimer’s Disease
capability that glial cells share with peripheral immunocom-
petent cells including monocytes and macrophages. In the
brain, phagocytosis is believed to be performed mainly by
microglia, but astrocytes also have this capability [6].
Under stress, glial cells proliferate and become activated,
which leads to production of neurotoxic molecules such as
free radical species and proinﬂammatory cytokines [7, 8].
In contrast to the potentially tissue-damaging responses,
glia can also produce factors that promote neuroprotection
and neuronal plasticity [9] .T h e s ep r o t e c t i v ea n ds u p p o r t i v e
functions may be downregulated during stress. Therefore,
inﬂammation in the brain may worsen the outcome of an
already existing trauma or pathological condition.
In the AD brain, activated microglia and astrocytes
are present in the areas of neurodegeneration and amyloid
plaques [10] and there is an increased production of proin-
ﬂammatory cytokines such as interleukin- (IL)-1 [11]a n d
IL-6 [12]. In addition, elevated levels of IL-1 and IL-6 have
been found in serum and cerebrospinal ﬂuid (CSF) from
AD patients [13, 14] .I nv i t r os t u d i e sh a v ed e m o n s t r a t e d
that Aβ peptides can indeed activate glial cells to produce
inﬂammatory factors [15–18], which can contribute to the
neurodegenerative process [19]. Evidence from studies on
rat cortical microglia showed that the smaller aggregational
forms of Aβsuch as oligomers are more potent in stimulating
glial secretion of proinﬂammatory cytokines [18]. IL-1
increases the production of APP in human glia [20], and the
APP gene contains a binding site for the prime inﬂammatory
transcription factor nuclear factor κB( N F κB) [21]. Further-
more, inﬂammation may shift processing of APP towards the
amyloidogenic pathway [22]. A consequence of the interac-
tions between inﬂammation and the APP/Aβ-peptide may
be a vicious circle [23], in which inﬂammation increases Aβ
levels through increased production and reduced clearance,
whichinturnresultsinneuronalcelldeathandaperpetuated
andincreasedglialactivationandreleaseofproinﬂammatory
factors, as well as neuronal cell death, and so forth.
Removal of a disease-causing pathogen is probably the
most eﬀective way of treating a disease. To stimulate cellular
uptake, phagocytosis of Aβ is a promising strategy. In studies
on animal models of AD, active and passive immunizations
have been shown to be eﬀective in removing plaques and to
improve cognitive performance [24]. Human clinical trials
withactiveimmunizationhavebeenstartedbutwereaborted
due to serious side-eﬀects in a few cases [25]. However,
several clinical trials with modiﬁed protocols, including
passive immunizations, are currently being carried out.
Phagocytosis is an activity that is performed primarily by
cells of the immune system, notably cells of the monocyte
lineage. In the light of the studies on active and passive
immunization we are presented with a strategy for treatment
of AD, to activate the immune system into phagocytosis of
Aβ.Althoughinﬂammationgenerallyisbelievedtostimulate
phagocytic activities, there is also evidence indicating that
inﬂammation may inhibit phagocytosis [26], whereas anti-
inﬂammatory cytokines such as transforming growth factor-
β (TGF-β) can stimulate phagocytosis [27]. Thus, it is of
importance to search for compounds that can promote
phagocytosis without starting the damaging processes of
inﬂammation.Inshort,directedanddiﬀerentialactivationof
immunecellsresidingin,ordestinedfor,theCNSconstitutes
a potential therapeutic target.
In the present study, the aim was to characterise the
responsesofhumanmicrogliatotheexposureofAβ.Inorder
to investigate the possibilities to increase glial uptake of Aβ
we have analysed the eﬀects of diﬀerent immunomodulatory
substances. The eﬀects of the adjuvant Protollin, as well as
those of the archetypical proinﬂammatory cytokines, IL-1β
and interferon-γ (IFNγ), were analysed in an in vitro model
of human microglial cells with regard to Aβ1–42 uptake,
microglial phenotype, and the secretion of IL-6 and brain-
derived neurotrophic factor (BDNF).
IL-6 is a cytokine that is induced by IL-1β and tumour
necrosis factor-α (TNFα) and can thus be considered a gen-
eral measure of inﬂammation [28]. BDNF is a neurotrophic
growth factor of importance in memory formation and
neuroprotection [29, 30]. Protollin is an adjuvant made
of Shigella ﬂexneri 2a lipopolysaccharides (LPS) associated
noncovalently to meningococcal outer membrane proteins
(proteosomes), that has been proven to be safe for use in
humans [31]. While LPS activates Toll-like receptor type 4
(TLR4), cd11, and cd14, proteosomes activate TLR2 [32].
Activation of TLR2 has been associated with increased
phagocytosis in mice with sciatic nerve lesions [33]. Fur-
thermore, intranasal application of Protollin was shown
to prevent accumulation of Aβ in young transgenic mice
expressing the human APP with the Swedish mutation and
also to stimulate clearance of Aβ from the brain of aged
mice of the same transgenic strain [34]. A correlation was
found between the removal of Aβ and the level of microglial
activation, as demonstrated by increased expression of the
activation marker CD11b in conjunction with the removal
of Aβ in animals treated with Protollin [34]. To investigate
the eﬀects of Protollin on cellular inﬂammatory markers,
and the association of these markers with uptake of Aβ1–42
by the human microglial cells, the expression of inducible
nitric oxide synthase (iNOS), IL-1β, and the signalling type
Ir e c e p t o rf o rI L - 1 β (IL-1RI) was analyzed in cells showing
uptake of Aβ1–42. iNOS is induced in inﬂammation and
shown to be harmful for neurons due to the production
of radical nitrogen species [35]. It has been shown to be
associatedwithneurodegenerativedisorderssuchasAD[36].
2.MaterialsandMethods
2.1. Chemicals. Protollin was provided by Glaxo-Smith
Kline Biologicals, Laval, Quebec, Canada. Aβ1–42 conju-
gated with HiLyteFluor488 or biotin was obtained from
Anaspec (Fremont, USA). Dimethylsulfoxide (DMSO),
Triton-X100, bovine serum albumin (BSA), 4 ,6-diamidino-
2-phenylindole (DAPI), and (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) were purchased
from Sigma, Stockholm, Sweden. Normal donkey and goat
serum and ﬂuorescence mounting medium were from
DakoPatts (Stockholm, Sweden). Streptavidin-7-amino-4-
methyl-3-coumarinylacetic acid (AMCA) is from Jackson
ImmunoResearch Europe Ltd (Suﬀolk, UK). Lactate deydro-
genase (LDH) assay is from Roche (Stockholm, Sweden).International Journal of Alzheimer’s Disease 3
ELISA-kits for IL-6 and BDNF are from R&D systems
(Abingdon, United Kingdom). IFNγ (Bachem, Weil am
Rhein, Germany). Cell culture medium, phosphate-buﬀered
saline (PBS), GlutaMaxII, foetal calf serum (FCS) and
PBS-based enzyme-free cell dissociation buﬀer (Invitrogen,
Stockholm, Sweden). Cell culture bottles and multiwell
plates (BD Biosciences, Stockholm, Sweden).
2.2. Cell Cultures. Human microglial cells (CHME3) were
obtained as a kind gift from Professor M. Tardieu (Neu-
rologie p´ ediatrique, Hˆ opital Bicˆ etre, Assistance publique,
Hˆ opitaux de Paris, Paris, France). CHME3 cells were
cultured in T75 or T175 bottles in culture medium
(DMEM/high glucose w/o sodium pyruvate supplemented
with 2mM L-glutamine or GlutaMaxII and 10% heat-
inactivated FCS). The cells were subcultured at conﬂuence
using enzyme-free cell dissociation buﬀer after washing once
with PBS without Mg2+ and Ca2+.
2.3. Experimental Procedures. The CHME3 microglial cells
were seeded in 48-well plates for analysis of cell viability
(MTT) and cytotoxicity (LDH), in 6-well plates for ﬂow-
cytometryandanalysisofsubstancesreleasedtothemedium,
or on glass coverslips in 24- or 48-well plates for immunocy-
tochemistry. All experiments were performed at a conﬂuence
of ∼60%. Aβ1–42 was dissolved in DMSO and stored in
darkness at +4◦C until use at a ﬁnal concentration of
1μg/mLforallexperimentsexceptforadose-responsecurve.
In higher doses we observed aggregate-like precipitates of
ﬂuorescent Aβ1–42 which were unwanted in this study. Before
the addition of Aβ1–42 or vehicle (DMSO), the cells were
prestimulated for 24 hours with either Protollin (0.001, 0.01
and 0.1μg/mL in serum-free culture medium) or cytokines
(50ng/mL IL-1β,5 0n g / m LI F N γ,o rI L - 1 β+IFNγ). At 0, 24,
48, 72, and 96 hours after addition of Aβ1–42 the cultures
were analyzed for uptake of Aβ1–42, expression of cellular
markers, and secretory products. Uptake of ﬂuorescent
Aβ1–42 bylivingcellswasanalysedinaNikonTE600-inverted
ﬂuorescence microscope. Cell viability and cell death were
also analysed.
2.4. Quantiﬁcation of Aβ1–42 Phagocytosis and Cellular Mark-
ers by Flow-Cytometry. After the experimental treatment,
the CHME3 microglial cells were dissociated with PBS-
based enzyme-free dissociation buﬀer as described above,
and centrifuged at 1500 ×g for 10 minutes. The cells were
then resuspended and ﬁxed in 1% para-formaldehyde (PF)
i nP B S ,f o r4 0m i n u t e sa tr o o mt e m p e r a t u r e ,a f t e rw h i c ht h e
ﬁxative was diluted 20× by addition of PBS and the cells
were centrifuged at 1500 ×g for 10 minutes. Fixation with
PF renders cells permeable to PI and therefore all ﬁxed cells
will be stained with PI, allowing the distinction of cells from
cell debris. Analysis was performed in a FACScalibur (BD)
ﬂow-cytometer. A detected event was deﬁned as a cell if it
was gated through the front-scatter (FSC) and side-scatter
(SSC) plot gate in addition to being positive for PI. A cell
positive for phagocytosis of Aβ1–42 (Aβ1–42+) was deﬁned
as a PI-positive cell that was also being positive for the
ﬂuorophore conjugated to Aβ1–42 (HyliteFluor488). Negative
controls were utilized to establish the limits of detection for
positive signals.
To investigate the phenotype of the cells with regard
to the presence of inﬂammatory markers, and the degree
of colocalization of each marker with phagocytosed Aβ1–42,
the cells were stained with antibodies directed against
human IL-1β (1:400; gift from Dr. Stefan Svensson, Statens
Bakteriologiska Laboratorium, Stockholm, Sweden), IL-1RI
(1:200; Amgen (Immunex Corporation) Thousand Oaks,
USA), and iNOS (1:600; R&D systems, London, England).
The cells were harvested and ﬁxed as described above and
subsequently an aliquot of the cell suspension was incubated
with the primary antibodies, diluted in PBS containing 5%
normal donkey serum and 0.1% Triton-X100. Omission of
primary antibodies served as negative control to establish the
limits of detection for positive signals. After incubation with
primary antibodies overnight at +4◦C, the cell suspension
was washed by addition of PBS followed by centrifugation at
2500 ×g for 20 minutes. The cells were resuspended in PBS
and incubated with donkey antigoat IgG-NL637 antibodies
(1:500; R&D systems, London, England) and PI for 1 hour
at room temperature. After incubation, the cell suspension
was diluted with PBS and analyzed by ﬂow-cytometry. A
celldisplayingimmunoreactivityforanantibodywasdeﬁned
as a cell showing a stronger signal in this channel than the
negative control. A cell displaying uptake of Aβ1–42 (Aβ1–42+)
was deﬁned as described above. The results were analysed
from a scatter plot with ﬂuorescence from the secondary
antibodyonthe y-axisandﬂuorescencefromHyliteFluor488
on the x-axis, divided into quadrants with borders based
on the negative controls as described. The cells were thus
being viewed in a two-way binary fashion with a cell being
present in a certain quadrant thus indicating (a) positive
forimmunoreactivitytoIL-1β(IL-1β+),IL-1RI(IL-1RI+),or
iNOS (iNOS+) and for Aβ1–42-uptake (Aβ1–42+), (b) positive
for immunoreactivity to one of these markers and negative
for Aβ1–42-uptake, (c) negative for immunoreactivity to the
markers and positive for Aβ1–42-uptake, or (d) negative for
immunoreactivity to the markers and for Aβ1–42-uptake. The
parameters extracted from the data were (a) total proportion
of the cells showing immunoreactivity to a marker, (b)
immunoreactivityofcellsnegativeforAβ1–42-uptake,and(c)
immunoreactivity of cells positive for Aβ1–42-uptake.
2.5. Immunocytochemistry and Staining of Fixed and Living
Cells for Microscopy. To analyse the microglial cell expression
of certain inﬂammatory markers and the localization of
phagocytosed Aβ1–42 by microscopy the culture medium was
removed and the coverslips dried at 37◦Cf o r∼2h o u r s .
The cells were ﬁxed with 4% PF for 20 minutes at room
temperature, washed in PBS, and incubated overnight at
4◦C with antibodies against IL-1β (1:400), IL-1RI (1:200),
and iNOS (1:600), respectively. The antibodies were diluted
in PBS containing 5% normal donkey serum and 0.1%
Triton-X100. After rinsing in PBS, the coverslips were
incubated for 1 hour at room temperature with goat
antirabbit-IgG conjugated with Cy2 (1:200), diluted in4 International Journal of Alzheimer’s Disease
PBS containing 5% normal goat serum, 0.1% Triton-X100,
and 1μg/mL PI. For visualization of biotinylated Aβ1–42,
streptavidin-AMCA was included in the secondary antibody
solution (2μg/mL). The coverslips were then washed with
PBS, mounted with ﬂuorescence mounting medium, and
inspected in a Nikon E800 microscope. To investigate the
targeting of Aβ1–42 toward degradation, cells were incubated
with HyliteFluor488-conjugated Aβ1–42 and then ﬁxed and
incubated overnight at 4◦C with mouse antibodies against
human lysosome-associated membrane protein-2 (lamp-2,
Millipore). After washing, the cells were incubated with
donkey antimouse antibodies conjugated with Cy3 and with
the nuclear stain DAPI and then mounted and inspected as
described above.
2.6. Enzyme-Linked Immunosorbent Assay (ELISA). The lev-
els of IL-6 and BDNF in the cell culture medium were
analyzed with commercially available ELISA-kits according
tothemanufacturer’sinstructions.Analysisofopticaldensity
(OD) was performed in a TECAN Saﬁre2 plate reader.
2.7. Cell Viability—MTT Assay. To analyse cell viability the
culture medium was removed and after washing with serum-
and phenol-free DMEM/high glucose with GlutaMaxII,
MTT (0.3mg/mL) was added and the cells incubated at 37◦C
for1hour.Thecrystalsformedbythereactionweredissolved
in DMSO and the OD was measured with a TECAN Saﬁre2
plate reader (Tecan, M¨ olndal, Stockholm) at 592nm with
620nm as a reference wavelength.
2.8. Cell Death—LDH Assay. To analyse cell death the
culture medium was removed and added to a 96-well
plate and then incubated with LDH-reagent according to
the manufacturer’s instructions. The OD was measured at
492nm with 620nm as reference wavelength.
2.9. Statistics. The data were normalized to vehicle (MTT-
assay, ELISA) Aβ1–42 (ﬂow-cytometry, for uptake) or positive
control(LDH-assay),ornotnormalized(ﬂow-cytometry,for
association of cellular markers with the uptake of Aβ1–42,
correlation between variables). The results were analysed
with Kruskal-Wallis nonparametric analysis of variance
(ANOVA) and the data were then compared pairwise using
the nonparametric Mann-Whitney U test with Bonferoni
correction. Pairwise comparison of variable within experi-
mental groups was performed with the Wilcoxon Matched
Pairs Test. Correlations between variables were analysed with
the Spearman’s Rank Order Correlation test. All statistical
analyses were performed in Statistica v8 (Statsoft).
3. Results
Human CHME3 microglial cells exposed to immunomodu-
latory substances were studied with regard to phagocytosis
of Aβ1–42 and expression of cellular markers (IL-1β,I L - 1 R I ,
and iNOS). As an indicator of an inﬂammatory response
we analysed the secretion of IL-6 in the culture medium. To
assess beneﬁcial and neuroprotective activities the secretion
of BDNF was determined. The levels of BDNF released
into the medium varied between 8 and 300pg/mL and the
levels of IL-6 varied between 20 and 950pg/mL under basal
conditions (vehicle group at 24 h). Cell death and viability
were also analysed.
The ability of CHME3 microglia to take up Aβ1–42
was conﬁrmed by inspection of living cells using phase
contrast/ﬂuorescence microscopy (Figure 1(a)), and ﬂuores-
cence microscopy on the ﬁxed cell suspension used for ﬂow-
cytometry (Figure 1(b)), and by confocal microscopy on
ﬁxed andliving cells (Figure 2). The ﬁrst signs of uptake (vis-
ible in inverted ﬂuorescence microscope) by the microglial
cells were observed approximately 4 hours after the addition
of Aβ1–42. Analysis of the intracellular content of Aβ1–42
was performed by ﬂow-cytometry at 24 and 96 hours after
addition of diﬀerent concentrations of Aβ1–42 (Figure 3(a)).
The uptake increased with increasing concentrations of
Aβ1–42. A 50-fold increase in the concentration of Aβ1–42
f r o m0 . 1t o5 μg/mL resulted in a 10-fold increase in the
fraction of cells taking up Aβ1–42 (P<. 05).
3.1. Eﬀects of Aβ1–42 on Secretion of BDNF and IL-6. In
dose-response experiments with 0.1, 0.5, 1, and 5μg/mL
of Aβ1–42, we found that 5μg/mL reduced the levels of
BDNF in the culture medium by 50% compared to vehicle
(P<. 01, Figure 3(b)). A similar degree of decrease was
seen for 5μg/mL Aβ1−42 when compared with the other
concentrations of Aβ1–42 (P<. 01). At 96 hours, the
concentrations of 0.1 and 0.5μg/mL Aβ1–42 slightly increased
the secretion of BDNF (P<. 05). No eﬀect was seen on the
secretion of IL-6 with the concentrations of Aβ1–42 tested
(Figure 3(b)).
3.2. Eﬀects of IL-1β and IFNγ on Uptake of Aβ1–42. To
evaluate the potential of stimulating CHME3 microglia into
phagocytosis by inﬂammation, the cells were incubated with
the proinﬂammatory cytokines IL-1β and IFNγ.P r e t r e a t -
ment with IFNγ resulted in an increase in the proportion of
cells showing Aβ1–42 uptake (Aβ1–42+ cells) with a median
increase of 50% at 72 hours (P<. 01, Figure 4,g r e yb o x e s ) ,
and the combined stimulation with IL-1β and IFNγ lead to a
median increase of 66% at 72 hours (P<. 01) as compared
tocontrols(withAβ1–42 alone)anda62%increasecompared
to IL-1β (P = .05). IL-1β alone had no signiﬁcant eﬀect on
the Aβ1–42 uptake. The observed eﬀects appeared to linger at
96 hours although the diﬀerences were not signiﬁcant.
3.3. Eﬀects of IL-1β and IFNγ on Secretion of BDNF and IL-
6. The levels of secreted BDNF were markedly reduced by
the incubation with the proinﬂammatory cytokines IL-1β
and IFNγ (Figure 5(a), white boxes). Thus, IFNγ decreased
the median secretion of BDNF as compared to vehicle with
41% at 72 hours and with 44% at 96 hours (P<. 05 at
both time points). There was no eﬀect of IL-1β alone, but
the combination of IL-1β and IFNγ resulted in a signiﬁcant,
almost 50%, decrease in BDNF secretion at 72 and 96 hours
(P<. 05 at both time points) (Figure 5(a), white boxes).International Journal of Alzheimer’s Disease 5
Phase contrast Aβ1–42 Merged
(a)
PI Aβ1–42 Merged
(b)
Figure 1: (a)-(b) Uptake of Aβ1–42 in human microglial cells. The micrographs in (a) show living human CHME3 microglial cells in culture
after incubation with Aβ1–42, seen by phase contrast and ﬂuorescence microscopy, and after merging of these. The micrographs in (b) show
ﬁxed CHME3 microglial cells in suspension after incubation with Aβ1–42, seen by ﬂuorescence microscopy with ﬁlters for propidium iodide
(PI) staining and HiLyte488-conjugated Aβ1–42, respectively, and the micrographs are merged in the 3rd micrograph. Magniﬁcations 10× (a)
and 40× (b).
Lamp-2
Aβ1–42
DAPI Merged
Figure 2: Uptake of Aβ1–42 in human microglial cells. The confocal micrograph (63×) shows ﬁxed CHME3 microglial cells demonstrating
intracellularlysosomallocationofHiLyte488-conjugatedAβ1–42 (greenﬁlter).Lysosomeswerevisualizedbystainingwithanantibodyagainst
lysosome-associated membrane protein-2 (lamp-2) and Cy3-conjugated secondary antibodies (red ﬁlter). Yellow colour thus indicates
colocalization of lamp-2 and HiLyte488-conjugated Aβ1–42.6 International Journal of Alzheimer’s Disease
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Figure 3: (a)-(b) Uptake of Aβ1–42 (a) and the concurrent secretion of interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF)
(b) by human CHME3 microglial cells at 24 and 96 hours. The cells were incubated with concentrations of Aβ1–42, ranging between 0.1 and
5μg/mL, or vehicle. The cells were harvested and the medium collected at 24 and 96 hours. In (a), the data are expressed as the proportion of
cells with intracellular Aβ1–42, n = 4. In (b), the data are expressed as % of control (vehicle) set at 100% and shown as median ± percentiles
(25%–75% and 10%–90%). There was a signiﬁcant eﬀect of the treatment on the uptake of Aβ1–42 at 24 hours (P = .0045) and at 96 hours
(P = .0375). The secretion of BDNF was also signiﬁcantly altered by the treatment at 24 hours (P = .0102) and at 96 hours (P = .0375).
Statistical diﬀerence from Aβ1–42,5μg/mL, is indicated by (P<. 01); statistical diﬀerence from vehicle is indicated by ∗∗(P<. 01).International Journal of Alzheimer’s Disease 7
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Figure 4: Eﬀects of Protollin (white boxes) and interleukin-1β (IL-1β) and interferon-γ (IFNγ)( g r e yb o x e s )o nt h eu p t a k eo fA β1–42 in
human CHME3 microglial cells. The cells were incubated with 1μg/mL Aβ1–42 following prestimulation for 24 hours with Protollin at
0.001–1μg/mL, or 50ng/mL IL-1β and 50ng/mL IFNγ. The cells were harvested at 24, 48, 72, and 96 hours after addition of Aβ1–42. The data
are expressed as % uptake of control Aβ1–42 set at 100%, and shown as median ± percentiles (25%–75% and 10%–90%), n = 19 (Protollin)
or n = 4 (cytokines) for 24 and 48 hours, and n = 17 (Protollin) of n = 6 (cytokines) for 72 and 96 hours. A statistically signiﬁcant eﬀect
of treatment was found by Kruskal-Wallis ANOVA at 96 hours when incubating microglia with Protollin (P = .0157) and at 72 hours when
incubating with IL-1β and/or IFNγ (P = .0022). Statistical diﬀerence from control is indicated by #(P<. 05), ##(P<. 01), and ###(P<. 005)
indicates statistical diﬀerence (P<. 01) between IL-1β and IL-1β+IFNγ.
Treatment of the cells with proinﬂammatory cytokines
resulted in a marked inﬂammatory response evidenced by
a dramatic increase in IL-6 secretion (Figure 5(b), white
boxes). At 0 hour (i.e., 24 hours after addition of the
cytokines and at the time point of addition of Aβ1–42,o r
in this case, vehicle), IL-1β and IL-1β+IFNγ stimulated
the IL-6 secretion, producing levels that were 50 and 90
times higher than control (vehicle), respectively (P<. 05
in both cases (Figure 5(b), white boxes). At 24 hours (i.e.,
after 48 hours incubation with the cytokines), IL-1β and
IL-1β+IFNγ induced a 200- and 140-fold increase in IL-
6 secretion, respectively, and the combination of IFNγ and
IL-1β resulted in a 25× higher induction than that by IFNγ
alone (P<. 05). The incubation with IL-1β+IFNγ was still
eﬀective at 96 hours in increasing secreted levels of IL-6
(P = .0108). At this time point, IL-1β alone and IFNγ alone8 International Journal of Alzheimer’s Disease
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Figure 5: (a)-(b) Eﬀects of incubation with interleukin-1β (IL-1β) and interferon-γ (IFNγ), added 24 hours before incubation with 1μg/mL
Aβ1–42 (black boxes) or vehicle (white boxes), on secreted levels of IL-6 (a) and BDNF (b) from CHME3 microglial cells. The cells were
incubated with 1μg/mL HiLyte488-conjugated Aβ1–42 following prestimulation for 24 hours with 50ng/mL IL-1β and 50ng/mL IFNγ.T h e
cells were harvested at 24, 48, 72, and 96 hours after addition of Aβ1–42. The data are expressed as % uptake of control vehicle set at 100% and
shown as median ± percentiles (25%–75% and 10%–90%), n = 4 for 24 hours and 48 hours and n = 6 for 72 and 96 hours. A statistically
signiﬁcant eﬀect of treatment was found by Kruskal-Wallis ANOVA at 24 hours (P = .0087), at 72 hours (P = .004), and at 96 hours
(P = .004). Statistical diﬀerence from control is indicated by ∗∗(P<. 01); diﬀerence from Aβ1–42 # is indicated by (P<. 05) and ##(P<. 01).
† indicates statistical diﬀerence (P<. 05) between IL-1β and IL-1β+IFNγ.
signiﬁcantly increased the levels of IL-6 several-fold (P<. 05
in both cases).
3.4. Eﬀects of IL-1β and IFNγ in Combination with Aβ1–42
on Secretion of BDNF and IL-6. Similarly to the eﬀect seen
for cytokines, the combined incubation of cytokines and
Aβ1–42 resulted in reduced secretion of BDNF (Figure 5(a),
black boxes). There was no eﬀect of Aβ1–42 alone on
secretion of BDNF in this series of experiments. At 24 hours,
pretreatment with IFNγ resulted in a median reduction to
77% in BDNF secretion compared to vehicle (100%) (P =
.0086).At72hours,themedianreductionwas25% (P<. 01)
and at 96 hours it was 45% (P<. 01) (Figure 5(a), black
boxes). The combination of Aβ1–42 with IFNγ pretreatment
resulted in signiﬁcantly lower secretion of BDNF than that
observed after treatment with Aβ1–42 alone at 72 hours
(P<. 01). Pretreatment with IL-1β decreased the median
BDNF secretion to 88% of vehicle at 96 hours (P<. 01).
At 72 hours, pretreatment with IL-1β+IFNγ resulted in a
signiﬁcant decrease in BDNF secretion to 64% of vehicle
secretion (P<. 01) which was also lower than the secretion
induced by Aβ1–42 alone at this time point (97% of vehicle,
P<. 01). This eﬀect was still present at 96 hours when
pretreatment with IL-1β+IFNγ resulted in a decrease in10 International Journal of Alzheimer’s Disease
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Figure 6: Uptake of Aβ1–42 and expression of cellular markers in human microglial cells. The micrographs show human CHME3 microglial
cells after incubation with biotinylated Aβ1–42, after which they were ﬁxed and stained with antibodies against interleukin-1β (IL-1β), IL-1
receptor type I (IL-1RI) and inducible nitric oxide synthase (iNOS), and subsequent incubation with Cy2-conjugated secondary antibodies.
Cell nuclei were stained with propidium iodide (PI) and the biotinylated Aβ1–42 was visualized with AMCA-conjugated streptavidin. All
micrographs are in 20× magniﬁcation.
BDNF level to 43% of vehicle (P<. 01), which also at this
time point was lower than the secretion induced by Aβ1–42
alone (88% of vehicle, P = .017). The pretreatment with
IL-1β+IFNγ also reduced the secretion of BDNF compared
with IL-1β at 72 hours (P<. 05).
Treatment of the cells with cytokines before addition
of Aβ1–42 (Figure 5(b), black boxes) resulted in a marked
increase in IL-6 secretion that paralleled the increase
observed in the absence of Aβ1–42 (Figure 5(b), white boxes).
In this series of experiments there were no eﬀects of Aβ1–42
alone at any time point on the secretion of IL-6. The
pretreatment of the CHME3 microglial cells with IL-1β
or IL-1β+IFNγ had a strong stimulatory eﬀect on the
secretion of IL-6 as compared to vehicle and to Aβ1–42 alone
(Figure 5(b), black boxes). At 24 hours, IL-1β increased the
median IL-6 secretion 25-fold compared with vehicle and
Aβ1–42 alone(P<. 01inbothcases).Asigniﬁcantstimulatory
eﬀect of IL-1β pretreatment was seen at 48 hours with levels
35-fold increase as compared to vehicle and Aβ1–42 alone
(P<. 01 in both cases). At 48 hours, a stimulatory eﬀectInternational Journal of Alzheimer’s Disease 11
of IFNγ became apparent, with a 5-fold increase in IL-6
secretion compared with vehicle and Aβ1–42 alone (P<. 01
in both cases). Compared with vehicle and Aβ1–42 alone, the
combined pretreatment with IL-1β+IFNγ induced a 35-fold
increase at 24 hours (P<. 01 in both cases) and a 28-fold
increase at 48 hours (P<. 01 in both cases). A 5-fold increase
was seen with the combined IL-1β+IFNγ treatment at 96
hours compared with vehicle (P<. 01). Also, the combined
stimulation with IFNγ and IL-1β prior to Aβ1–42 resulted in
an increase of almost 6 times in the mean secretion of IL-6
a t4 8h o u r sa sc o m p a r e dt oI F N γ alone (P<. 005), but not
compared to IL-1β.
3.5. Eﬀects of Protollin on Uptake of Aβ1–42. Pretreatment of
the microglial cells with Protollin at 0.001μg/mL was found
to increase the median proportion of cells showing uptake
of Aβ1–42 to 115% (P<. 05) as compared to control (Aβ1–42
alone, 100%, Figure 4). This eﬀect was seen at 96 hours, but
no signiﬁcant changes in any direction could be detected at
the earlier time points.
3.6. Eﬀects of Protollin, with and without Aβ1–42,o nS e c r e t i o n
of BDNF and IL-6. Treatment with Protollin alone, that is,
prior to addition of vehicle, did not aﬀect the secretion of
BDNF (data not shown). The incubation with Aβ1–42 alone
resulted in a decrease in the secretion of BDNF in this series
of experiments, that is, a reduction to 82% of vehicle at 24
hours (P<. 0000001), to 77% of vehicle at 48 hours (P<
.005) and to 95% of vehicle at 96 hours (P<. 05).
In cultures pretreated with the lowest concentration of
Protollin (0.001μg/mL) followed by incubation with Aβ1–42
there was a 22% reduction at the 24 hours time point
as compared to vehicle (P = .05), whereas at the higher
concentrations of Protollin and at later time points there
was no signiﬁcant diﬀerences in the secretion of BDNF in
comparison with control conditions (no Protollin and no
Aβ1–42).
Pretreatment with Protollin followed by Aβ1–42 or vehicle
did not induce any signiﬁcant eﬀects on the levels of IL-6 in
culture supernatants (data not shown).
3.7. Cellular Markers and Relation to Phagocytosis of Aβ1–42.
The uptake of Aβ1–42 in cells expressing the inﬂammatory
markers IL-1β, IL-1RI, and iNOS in the cultures treated with
Aβ1–42 following pretreatment with Protollin was demon-
stratedbyimmunocytochemistry(Figure 6).Theproportion
of cells positive for these markers was analysed by ﬂow-
cytometry, both after incubation with Aβ1–42 alone and after
pretreatment with Protollin, in order to assess the phenotype
of the cells taking up Aβ1–42 (Aβ1–42+) (Figure 7).
3.8. IL-1β Immunoreactive Cells. In untreated (vehicle)
cultures, the proportion of CHME3 microglial cells with
immunoreactivity to IL-1β had a median of 2.9% at 24
hours. Incubation of the cells with 1μg/mL Aβ1–42 did not
signiﬁcantlyaﬀectthenumberofIL-1β immunoreactivecells
compared with vehicle at any time point (Figure 7(a)).
The expression of IL-1β in Aβ1–42+c e l l sw a sn o t
signiﬁcantly diﬀerent from that in Aβ1–42− cells according to
the Wilcoxon Matched Pairs test, except at 72 hours when
the population of Aβ1–42+/IL-1β+ cells was larger than the
Aβ1–42−/IL-1β+c e l lp o p u l a t i o n( Figure 7(a)).
Pretreatment with Protollin increased the number of IL-
1β+ cells displaying Aβ1–42 uptake (Figure 7(a)). Signiﬁcant
diﬀerences were observed between Aβ1–42+/IL-1β+ cells and
Aβ1–42−/IL-1β+ cells treated with Protollin at 24 hours in
concentrationsof0.001μg/mL(P<. 05),0.1μg/mL(P<. 05)
and 1μg/mL (P<. 05), at 48 hours in concentrations of
0.1μg/mL (P<. 05) and 1μg/mL (P<. 05), and at 72 hours
in a concentration of 0.1μg/mL (P<. 05).
3.9. IL-1RI Immunoreactive Cells. In untreated (vehicle)
cultures the proportion of CHME3 microglial cells with
immunoreactivity for IL-1RI (IL-1RI+) had a median value
of 12.5% at 24 hours. Incubation with 1μg/mL Aβ1–42,w i t h
or without pretreatment with Protollin, did not signiﬁcantly
aﬀectthenumberofIL-1RIimmunoreactivecellsatanytime
point (Figure 7(b)).
When incubated with Aβ1–42 alone, the population
of Aβ1–42+/IL-1RI+ cells was signiﬁcantly larger than the
Aβ1–42−/IL-1RI+ population at 24, 48, and 72 hours (P<
.05, Figure 7(b)). When pretreated with Protollin, there was
a signiﬁcantly larger proportion of Aβ1–42+ cells that were
immunoreactive to IL-1RI (Aβ1–42+/IL-1RI+) at 24 hours in
concentrationsof0.001μg/mL(P<. 05),0.1μg/mL(P<. 05)
and 1μg/mL (P<. 05), at 48 hours in concentrations of
0.1μg/mL (P<. 05) and 1μg/mL (P<. 05) and at 72 hours
in a concentration of 0.1μg/mL (P<. 05).
3.10. iNOS Immunoreactive Cells. In untreated (vehicle) cul-
tures the median proportion of CHME3 microglial cells with
immunoreactivity to iNOS (iNOS+) had a median of 16%
at 24 hours under basal (vehicle) conditions. None of the
treatmentsaﬀectedthetotalnumberofcellsimmunoreactive
for iNOS (Figure 7(c)).
When incubated with Aβ1–42 alone, the population
of Aβ1–42+/iNOS+ cells was signiﬁcantly larger than the
population of Aβ1–42−/iNOS+ cells at all time points (P =
.0173 at 24 hours, P = .0172 at 48 hours, P = .0117 at 72
hours, and P = .05 at 96 hours, Figure 7(c)). Also when
cells were pretreated with Protollin, the Aβ1–42+/iNOS+
population was signiﬁcantly larger than the Aβ1–42−/iNOS+
population, at all concentrations tested (0.001μg/mL: P =
.0117 at 24 hours, P = .0357 at 48 hours and P = .025 at 72
hours; 0.01μg/mL:P = .0117 at 24 hours and P = .0117 at
48 hours; 0.1μg/mL:P = .0117 at 24 hours, P = .05 at 48
hours and P = .0251 at 72 hours: and P = .025 at 72 hours:
0.1μg/mL:P = .0117 at 24 hours, Figure 7(c)).
3.11. Correlation between Secretion of BDNF and Uptake of
Aβ1–42. We found a signiﬁcant negative correlation (P<. 05)
between the levels of BDNF in culture supernatant and the
proportion of Aβ1–42+ cells at all time points in the experi-
ments (Figure 8). The data were analysed by correlating the
BDNF-levels with the proportion of Aβ1–42+ cells in all the12 International Journal of Alzheimer’s Disease
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Figure 7: (a)–(c) Diﬀerential phenotype of human CHME3 microglia, in the populations of cells displaying (Aβ1–42+, grey boxes) or not
displaying (Aβ1–42−, white boxes) phagocytosis of Aβ1–42, with regard to immunoreactivity for interleukin-1β (IL-1β), inducible nitric oxide
synthase (iNOS), and IL-1β receptor type I (IL-1RI), following pretreatment with Protollin (0.001–1μg/mL). After 24–96 hours of exposure
to Aβ1–42, the cells were subjected to immunocytochemistry and analysed by ﬂow-cytometry. The population of cells with immunoreactivity
to the diﬀerent markers within the Aβ1–42+ cell population was compared with the corresponding population in the Aβ1–42− cell population
in each treatment group, using the Wilcoxon Matched Pairs Test. The data are shown as median ± percentiles (25%–75% and 10%–90%),
n = 7. Statistical diﬀerences between the Aβ1–42+ and Aβ1–42− cells with regard to each marker are indicated by ∗(P<. 05).
treatments at one time point, and in one treatment at one
time point, using Spearman’s Rank Order Correlation test.
There was a signiﬁcant negative correlation in all analyses
performed, except at 48 hours, when the treatment with
0.001mg/mL Protollin was void of a signiﬁcant correlation.
3.12. Cell Death and Viability. The eﬀects of Aβ1–42 and the
immunomodulatory substances on cell death and viability
wereanalysedbytheLDHandMTTassays,respectively.Nei-
ther Aβ1–42 nor Protollin, nor their combination, produced
any signiﬁcant eﬀects on cell viability (data not shown).International Journal of Alzheimer’s Disease 13
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Figure 8: Correlation between the secretion of BDNF and the proportion of Aβ1–42+ cells. The secretion of BDNF (pg/mL) and the
proportionofAβ1–42+cellsintheProtollinseriesofexperimentswereanalysedateachtimepointusingSpearman’sRankOrderCorrelations
test. A signiﬁcant negative correlation was found at all time points. A statistical signiﬁcant correlation is indicated by ∗(P<. 05).
The incubation with IFNγ or IL-1β+IFNγ decreased the
signal from the MTT assay signiﬁcantly to almost 50% of
vehicle starting at 48 hours (P<. 05), and at 72 (P<. 005)
and 96 hours (P<. 005) (Figure 9). This eﬀect was seen both
when the microglia were stimulated with the cytokines alone
and when they were added before Aβ1–42.
There were no signiﬁcant diﬀerences in the LDH-activity
in the medium from any of the treatments (not shown).
Inspection with microscope, however, showed signs of cell
death in treatments associated with a signiﬁcant decrease in
MTT signal.
4. Discussion
In this study, a human microglial cell line was used to model
phagocytosis of Aβ and to evaluate the eﬀects of diﬀerent
substances. The ability to analyse the eﬀects of diﬀerent
substances with a human microglial cell line, which can be
cultured in signiﬁcant quantities, and the cellular reactions
to pathological factors, such as Aβ,i sav a l u a b l et o o li n
studies of human CNS-pathologies. The CHME3 cell line
was established by Professor Tardieu (see [37]). This cell line
responds to stimulation with LPS by increased secretion of
IL-6 [38], a cytokine also secreted under basal conditions.
We have found that CHME3 microglial cells also secrete low,
but detectable, levels of IL-1β and TNFα as well as other
cytokines (unpublished observations).
Phagocytosis of Aβ1–42 was established using
ﬂuorophore-labelled Aβ1–42. The uptake was ﬁrst detectable
at4hoursaftertheaddition asseenbymicroscopicalanalysis
of living cells. Phagocytosis of Aβ1–42 was diﬀerentiated from
unspeciﬁc adherence to cell membranes by confocal
microscopy which conﬁrmed the lysosomal location of
Aβ1–42. In terms of inﬂammatory response, the incubation
with Aβ1–42 at the concentration used (1μg/mL) did not
aﬀect the basal secretion of IL-6, in accordance with studies
on primary human embryonic microglia in which Aβ1–42
failed to increase transcription of the IL-6 gene and Aβ25–35
had no eﬀect on IL-6 secretion [39]. Similarly, the secretion
of IL-6 from rat microglial cells was not altered upon
incubation with 75 μMA β1–42, a concentration 150-fold the
concentration used in this study [18]. In contrast, primary
mouse microglia have been shown to respond with markedly
increased IL-6 secretion upon stimulation with Aβ1–42 in
a concentration similar to that in the present study [40],
indicating a species diﬀerence. In our previous studies on the
CHME3 microglia a marked increase in the secreted levels
of IL-6 could be seen upon incubation with Aβ1–40 [38],14 International Journal of Alzheimer’s Disease
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Figure 9: Eﬀects of interleukin-1β (IL-1β) and interferon-γ (IFNγ) on cell viability in human CHME3 microglial cells treated with Aβ1–42
(grey boxes) or vehicle (white boxes). The cells were preincubated with 50ng/mL IL-1β and 50ng/mL IFNγ for 24 hours prior to addition of
Aβ1–42 (1μg/mL). At 24, 48, 72, and 96 hours after addition of Aβ1–42 the viability of the cultures was assessed with the MTT assay. The data
are expressed as % of control (vehicle) set at 100% and shown as median ± percentiles (25%–75% and 10%–90%), n = 4 (24, 48 h), n = 6
(72, 96 h). Statistical diﬀerence from vehicle is indicated by ∗(P<. 05) and ∗∗∗(P<. 005), and statistical diﬀerence from Aβ1–42 is indicated
by #(P<. 05) and ##(P<. 01). łł(P<. 01) indicates statistical diﬀerence between IFNγ and IL-1β+IFNγ,a n d†(P<. 05) indicate diﬀerences
between IL-1β and IL-1β+IFNγ.
suggesting a diﬀerence in the immune-activating properties
of the two forms of Aβ.
We show here that the human microglial cell line
produces and secretes BDNF, in agreement with studies
on human post mortem tissue [41]. Studies in diﬀerent
injury models in animals have shown the induction of
BDNF production in microglia [42], supporting a view of
BDNF as a glial response to neuronal injury serving to help
neurons to recover. In this context it is remarkable that
the incubation with Aβ1–42 reduced the secretion of BDNF,
which to our knowledge is the ﬁrst time that Aβ1–42 has been
shown to exert this eﬀect on any cell type. This adds to the
negative eﬀects of Aβ1–42 and indicates a further reason for
limiting the amyloidosis in AD. Evidence for detrimental
interference by Aβ1–42 on BDNF signalling in neurons has
been provided previously [43]. A reduced secretion and an
impairedsignallingofBDNFmaycontributetothecelldeath
and impaired neuronal function in AD. In fact, decreasedInternational Journal of Alzheimer’s Disease 15
levelsofBDNFhavebeenobservedintheCSFofADpatients,
and at later stages of the disease this reduction correlated
with the severity of impairment [44].
Interestingly, a marked decrease in basal BDNF secretion
was observed also upon incubation of the microglial cells
with IFNγ,a ne ﬀect that was also observed upon coincu-
bation with IL-1β. In contrast, studies on rodent microglia
showed an increase in the levels of BDNF in association with
inductionofinﬂammation[42],againsuggestingspeciesdif-
ferences in microglial responses. Furthermore, studies on rat
astrocytes indicated a stimulating eﬀect on BDNF produc-
tion by TNFα mediated by NFκB[ 45]. In the present study
IL-1β, which is also known to activate NFκB[ 46], caused a
mild inhibitory eﬀect on BDNF secretion at 96 hours.
To analyse the possibility to stimulate the phagocytosis
of Aβ1–42, we analysed the eﬀects of diﬀerent immunomod-
ulatory substances. Pretreatment of the human microglial
cells with IFNγ, alone or together with IL-1β,r e s u l t e di na
signiﬁcant increase in the proportion of cells with an uptake
of Aβ1–42. This was accompanied by a pronounced reduction
in BDNF secretion, as well as decreased cell viability. The
results indicate that proinﬂammatory factors may be able
to stimulate Aβ1–42 phagocytosis. However, the stimulation
by IFNγ was seen in the later time points and it may be
speculated that the acute inﬂammation at the start of the
experiment had expired at this stage with presumably only
low levels of the added cytokines still present in the medium.
The eﬀects observed may thus be due to factors induced
by and secondary to IFNγ. The eﬀect of long-term, chronic
exposure to inﬂammatory stimulation may be diﬀerent.
The inﬂuence of inﬂammation on Aβ1–42 phagocytosis and
clearance is a complex matter, where factors such as age
and species may be pivotal. Even more complexity is added
by the eﬀects of Aβ1–42 itself on inﬂammation, including
the ﬁndings that the 40 and 42 amino acid peptides, and
the aggregational form of Aβ1–42 (monomers, oligomers,
protoﬁbrils, etc.), induce diﬀerent inﬂammatory responses
as seen in studies on rat microglia [18]. Furthermore, the
shorter and longer species of Aβ have not been characterized
with regard to their inﬂuence on glia. In the present study
we prepared Aβ1–42 by dissolving the lyophilized peptide
in pure DMSO, and therefore it is reasonable to assume
that soluble monomers or oligomers dominate at the start
of the experiments. Interestingly, we could not detect any
signiﬁcant diﬀerence in the proportion of Aβ1–42+ cells with
time (data not shown). Factors inﬂuencing this proportion
may be the rate of phagocytosis, degradation of the peptide,
or changes in cell number. Our data show an ongoing cell
proliferation continuing to the end of the experiment. This
fact, taken together with a stable Aβ1–42+c e l lp r o p o r t i o n
with time, suggests that phagocytosis is continuous. An
exception was seen upon treatment with IFNγ,i nw h i c h
the Aβ1–42+ proportion increased signiﬁcantly simultaneous
with a reduction in cell viability.
Protollin, a proteosome-based adjuvant with immuno-
modulatory activities, was found to modestly increase Aβ1–42
uptake by the human CHME3 microglia at 96 hours after
addition of Aβ1–42, but not at the earlier time points
and only at the lowest concentration tested (0.001μg/mL).
This potentially stimulatory eﬀect of Protollin on Aβ1–42
uptake is concordant with results from in vivo studies on
Protollin in an AD mouse model [34], showing clearance of
amyloid plaques and improved cognitive performance upon
intranasal administration of Protollin. The limited eﬀect of
Protollin in the present in vitro experiments as compared
to the in vivo studies may have several explanations. In the
mouse in vivo model, the stimulatory eﬀect of Protollin
on Aβ-uptake appears to be mediated via activation of
monocytes in the periphery that migrate to the brain and
phagocytose Aβ, rather than direct activation of microglial
cells resident in the brain [34]. Also, there was no evidence
from the in vivo studies that Protollin translocates to
the brain following nasal administration [34]. The modest
stimulatory eﬀect of Protollin on Aβ1–42 uptake by microglial
cells in the present study may reﬂect the absence of accessory
cells in the in vitro cultures, that is, cells that Protollin
directly activates in the periphery in vivo. Alternatively,
considering that the eﬀect of Protollin did not become
apparent until the later part of the experiment, it may also
be speculated that activation of microglial cell precursors by
Protollin in the periphery results in the secretion of factors
in a para/autocrine fashion, that with time build up to con-
centrations that stimulate phagocytosis. Species diﬀerences
should also be considered. The response repertoire of glial
cells appears to be diﬀerent in human as compared with
murine cells [47, 48].
Interestingly,thepretreatmentwithProtollinappearedto
ameliorate the Aβ1–42-induced decrease in BDNF secretion.
This highlights a therapeutic target: stimulation of glial
cells for the production of beneﬁcial and neuroprotective
molecules. As indicated above, beneﬁcial eﬀects of Protollin
in the context of immunotherapy may be elicited through
stimulation of peripheral monocytes [34], directly, or indi-
rectly through interaction with other immunocompetent
cells. The present data, for example, on BDNF, suggest that
Protollin or similarly acting substances may also stimulate
beneﬁcial eﬀects on glial cells within the brain.
To our knowledge, no studies on human cells have until
now investigated the eﬀects of TLR2 activation on BDNF
secretion. A strong negative correlation between the Aβ1–42+
cellproportionandthesecretionofBDNFwasalsoobserved.
This result can be due to a negative eﬀect on phagocytosis by
BDNF or a decrease in BDNF secretion by cells performing
phagocytosis. In a previous study BDNF was found to
stimulate phagocytosis [49]. Although the experiments were
performed on mouse peritoneal macrophages, the results
support the latter explanation for the negative correlation
between BDNF levels and phagocytosis.
Analysis with ﬂow-cytometry showed that cells dis-
playing phagocytosis of Aβ1–42 had a signiﬁcantly higher
degree of expression of IL-1RI and iNOS, indicating that
phagocytosis of Aβ1–42 was associated with an inﬂammatory
phenotype. Similarly, in a mouse AD-model, the expression
of CD11b, a microglial activation marker that has been used
as an indicator of harmful inﬂammation in several studies,
was associated with removal of Aβ [34].
Protollin appeared to decrease the proportion of iNOS+
cells displaying phagocytosis of Aβ1–42, although the total16 International Journal of Alzheimer’s Disease
number of iNOS+ cells remained unchanged. This pro-
portion was signiﬁcantly higher at all time points when
incubated with Aβ1–42 alone. At 96 hours, the pretreatment
with Protollin abolished this diﬀerence. A reduction in the
levels of iNOS is beneﬁcial due to the contribution of this
enzyme to oxidative stress, supporting beneﬁcial eﬀects of
Protollin.
Thedecreaseincellviabilityaccompanyingtheinduction
of Aβ phagocytosis by IFNγ and IL-1β suggests microglial
celldeath.Thiswasconﬁrmedbymicroscopicalinspectionof
the cultures. In spite of this, there was no detectable increase
in the LDH-activity. However, a decrease in cell number
as indicated by the MTT-assay could mask an increase
in cell death as measured by the LDH-assay since fewer
cells are available to release LDH into the medium. IFNγ
has been shown to induce cell death in murine microglia,
concomittant with an upregulation of the expression of Fas
and FasL [50]. In addition, IL-1β and IFNγ are known to be
involved in the expression and activation of iNOS [51, 52],
which in turn may lead to oxidative stress.
In conclusion, we provide a model suitable for testing
candidates for stimulating the phagocytosis of Aβ1–42 by
human microglial cells. The capacity to withstand serum-
withdrawal for long periods of time and the high rate of
proliferation makes the human CHME3 cell line suitable for
this type of studies. Expanding primary cultures of microglia
for large experimental series is not trivial. The data presented
indicate diﬀerences between human microglial cells and
murine glia, as described in other studies. In the present
study, we show that the immunomodulatory substance
Protollin aﬀects the proportion of cells phagocytosing Aβ
and their expression of inﬂammatory markers. Pretreatment
with IFNγ had a robust stimulatory eﬀect on phagocytosis of
Aβ1–42 at later time points, suggesting inﬂuence of secondary
factors induced by this cytokine. In addition, we present data
suggesting a neuropathological role for IFNγ by decreasing
BDNF levels. Importantly, we show a strong negative eﬀect
of Aβ1–42 on BDNF secretion. If phagocytic cells indeed have
a decreased secretion of BDNF, as indicated by the negative
correlation between phagocytosis and BDNF, this suggests
an interesting parameter for future evaluation of potential
drugs. The results present a scenario in which inﬂammation
increases phagocytosis of Aβ1–42, induces microglial cell
death, and reduces secretion of BDNF. The reduction in
BDNF is unwanted, since it deprives the brain of an
important neuroprotective and plasticity-promoting factor.
Considering the presence of inﬂammation in AD, it may be
suggested that the combined eﬀect of Aβ,I L - 1 β,a n dI F N γ
on the secretion of BDNF from microglia may contribute to
the neuronal pathology in AD. We hope that this and future
studies can help develop directed and controlled activation
of diﬀerential pro- and anti-inﬂammatory responses for
therapeutic use.
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